Structures, Chemical Probes, New Biology, New Targets for Drug Discovery: Is This the Right Sequence?
with Chas Bountra, Ph.D., Professor, Translational Medicine; Head, Structural Genomics Consortium, University of Oxford
CHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.
Using Structure and Property-Based Methods to Create a Quality ITK Inhibitor
with Jason Burch, Ph.D., Scientist, Medicinal Chemistry, Genentech
At the upcoming Structure-Based Drug Design conference in Boston, Dr. Jason Burch, a Medicinal Chemist at Genentech will give a talk on structure-based design and property optimization of potent and selective pyrazole carboxamide interleukin-2 inducible t-cell kinase (itk) inhibitors for the treatment of inflammatory diseases. CHI recently spoke with Dr. Burch about why he chose to pursue ITK inhibitors, important considerations for developing these types of inhibitors, and what techniques were used to improve pharmaceutical properties of the lead matter. Dr. Burch also discusses how advances in genomics and demand for personalized treatments has changed drug design techniques.